Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
NCT00051103
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Metastatic Breast Cancer
Neoplasms, Breast
Interventions
DRUG:
Investigational Cancer Drug
Sponsor
GlaxoSmithKline